JP2018115218A5 - - Google Patents

Download PDF

Info

Publication number
JP2018115218A5
JP2018115218A5 JP2018089165A JP2018089165A JP2018115218A5 JP 2018115218 A5 JP2018115218 A5 JP 2018115218A5 JP 2018089165 A JP2018089165 A JP 2018089165A JP 2018089165 A JP2018089165 A JP 2018089165A JP 2018115218 A5 JP2018115218 A5 JP 2018115218A5
Authority
JP
Japan
Prior art keywords
oral administration
formulation
disease
peak
administration according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018089165A
Other languages
English (en)
Other versions
JP2018115218A (ja
JP6657294B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018115218A publication Critical patent/JP2018115218A/ja
Publication of JP2018115218A5 publication Critical patent/JP2018115218A5/ja
Application granted granted Critical
Publication of JP6657294B2 publication Critical patent/JP6657294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (8)

  1. （２Ｓ，３Ｓ）−２−アミノ−３−メチル−Ｎ−（２−モルホリノエチル）−ペンタンアミドの硫酸付加塩の結晶形態および薬学的に許容される賦形剤若しくは担体を含む経口投与用製剤。
  2. 前記結晶形態が、約19.277±0.5°；21.784±0.5°；および22.468±0.5°の２θにピークを含むＸ線粉末回折パターンを示す、請求項１に記載の経口投与用製剤。
  3. 前記Ｘ線粉末回折パターンが、さらに約20.208±0.5°；24.618±0.5°；および27.178±0.5°の２θにピークを含む、請求項２に記載の経口投与用製剤。
  4. 前記結晶形態が、さらに約1033±10cm -1 ；975±10cm -1 ；および851±10cm -1 のピークを含むラマンスペクトルを示す、請求項２または３に記載の経口投与用製剤。
  5. 前記ラマンスペクトルが、さらに約1447±10cm -1 ；1308±10cm -1 ；および772±10cm -1 のピークを含む、請求項４に記載の経口投与用製剤。
  6. p75を発現する細胞の退化または機能不全を伴う障害の治療、緩和または防止における使用のための、請求項１乃至５のいずれか一項に記載の経口投与用製剤。
  7. 神経変性障害の治療、緩和または防止における使用のための、請求項１乃至６のいずれか一項に記載の経口投与用製剤。
  8. アルツハイマー病、ハンチントン病、ピック病、筋萎縮性側索硬化症、てんかん、パーキンソン病、脊髄損傷、脳卒中、低酸素症、虚血、脳損傷、糖尿病性ニューロパシー、末梢性ニューロパシー、神経移植と関連する障害、多発性硬化症、末梢神経損傷、および脱毛からなる群から選択される障害の治療、緩和または防止における使用のための、請求項１乃至７のいずれか一項に記載の経口投与用製剤。
JP2018089165A 2009-11-12 2018-05-07 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態 Active JP6657294B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US26067109P 2009-11-12 2009-11-12
US61/260,671 2009-11-12
US29427910P 2010-01-12 2010-01-12
US61/294,279 2010-01-12
US35079710P 2010-06-02 2010-06-02
US61/350,797 2010-06-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015200793A Division JP2016020380A (ja) 2009-11-12 2015-10-09 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態

Publications (3)

Publication Number Publication Date
JP2018115218A JP2018115218A (ja) 2018-07-26
JP2018115218A5 true JP2018115218A5 (ja) 2019-01-17
JP6657294B2 JP6657294B2 (ja) 2020-03-04

Family

ID=43992064

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012539022A Active JP5863663B2 (ja) 2009-11-12 2010-11-12 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
JP2015200793A Pending JP2016020380A (ja) 2009-11-12 2015-10-09 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
JP2018089165A Active JP6657294B2 (ja) 2009-11-12 2018-05-07 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012539022A Active JP5863663B2 (ja) 2009-11-12 2010-11-12 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
JP2015200793A Pending JP2016020380A (ja) 2009-11-12 2015-10-09 ニューロトロフィン模倣化合物およびこれらの塩の結晶形態

Country Status (10)

Country Link
US (3) US9271986B2 (ja)
EP (2) EP3470402B1 (ja)
JP (3) JP5863663B2 (ja)
CN (3) CN104761515B (ja)
AU (1) AU2010319349B2 (ja)
CA (2) CA2780940C (ja)
ES (1) ES2712752T3 (ja)
HK (1) HK1212970A1 (ja)
IN (1) IN2012DN05142A (ja)
WO (1) WO2011060262A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
AU2010319349B2 (en) 2009-11-12 2015-07-16 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CN104995180A (zh) * 2012-09-27 2015-10-21 特罗菲克斯制药股份有限公司 神经营养因子模拟化合物及其盐的结晶形式
WO2016196804A1 (en) * 2015-06-04 2016-12-08 Balchem Corporation Hydration control for choline salts
US11215532B2 (en) 2020-05-04 2022-01-04 Ford Global Technologies, Llc Methods and systems for exhaust gas recirculation system diagnostics

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3541130A (en) 1967-02-06 1970-11-17 Boehringer Sohn Ingelheim 1-(cyanophenoxy)-2-hydroxy-3-tert.-butylamine propanes
US4613676A (en) * 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
US4743607A (en) 1987-05-29 1988-05-10 Merrell Dow Pharmaceuticals Inc. Cardiotonic tricyclic imidazolones
JPH04503205A (ja) 1988-05-02 1992-06-11 ナフッチィ，エヌ，エリック 神経学的活性化合物
US5028622A (en) 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5321029A (en) 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
CA2010531A1 (en) 1989-03-06 1990-09-06 Werner Neidhart Amino acid derivatives
DE59205565D1 (de) 1991-10-07 1996-04-11 Hoechst Ag Carbonsäureester-Schutzgruppen, ein Verfahren zu ihrer Herstellung, ihre Kopplung an eine funktionelle Gruppe sowie ihre Verwendung
US5608067A (en) 1993-12-09 1997-03-04 Afonso; Adriano 4-substituted pyrazoloquinoline derivatives
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
JPH08119922A (ja) 1994-10-21 1996-05-14 Torii Yakuhin Kk ｏ−ピバロイル−チロシン誘導体
WO1996016980A1 (en) * 1994-11-29 1996-06-06 Novartis Ag Morpholinoethylamide derivatives
JPH1081661A (ja) 1995-10-23 1998-03-31 Sankyo Co Ltd ヒドロキサム酸誘導体
US5958875A (en) 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
EP0890105B1 (en) 1996-03-29 2006-11-22 The Trustees Of Boston University Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
WO1997042168A1 (en) 1996-05-06 1997-11-13 Zeneca Limited Thio derivatives of hydroxamic acids
GB9613547D0 (en) 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
GB9715962D0 (en) 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
CA2281545C (en) 1997-02-19 2007-04-24 Berlex Laboratories, Inc. N-heterocyclic derivatives as nos inhibitors
FR2762315B1 (fr) 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
AU7698998A (en) 1997-05-30 1998-12-30 Neurex Corporation Substituted peptidylamine calcium channel blockers
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US20020022657A1 (en) 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
WO1999050264A1 (fr) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Derives de quinazoline
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
KR20010100983A (ko) 1998-11-06 2001-11-14 로셰 디아그노스틱스 게엠베하 매트릭스 메탈로프로테아제 관련 질환 치료제용 시스틴유도체
US6472418B1 (en) 1998-12-18 2002-10-29 Warner-Lambert Company Non-peptide NK1 receptors antagonists
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
DE19939910A1 (de) 1999-08-23 2001-03-01 Morphochem Ag Neue Verbindungen, die Tryptase-Aktivität hemmen
AU7353300A (en) * 1999-09-08 2001-04-10 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
WO2001042208A1 (fr) 1999-12-08 2001-06-14 Teijin Limited Antagonistes du recepteur ccr5 de la cycloamine
AU2001228212A1 (en) 2000-01-18 2001-07-31 Mcgill University Beta-turn peptidomimetic cyclic compounds
AR028606A1 (es) 2000-05-24 2003-05-14 Smithkline Beecham Corp Nuevos inhibidores de mmp-2/mmp-9
US6699989B1 (en) 2000-08-28 2004-03-02 B. Vithal Shetty Antiviral and antimicrobial guanidine or biguanidine derivatives
WO2002048660A1 (en) 2000-12-13 2002-06-20 Spelman College Multiplex coherent raman spectroscopy detector and method
JP4278511B2 (ja) 2001-07-11 2009-06-17 イーラン ファーマスーティカルズ、インコーポレイテッド Ｎ−（３−アミノ−２−ヒドロキシ−プロピル）置換アルキルアミド化合物
US20040248984A1 (en) 2001-08-29 2004-12-09 Josef Krieglstein Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
WO2003030836A2 (en) * 2001-10-12 2003-04-17 Case Western Reserve University Neuronal regeneration
AU2002359376B2 (en) 2001-11-08 2008-01-10 Elan Pharmaceuticals, Inc. N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
WO2003092580A2 (en) * 2002-05-03 2003-11-13 Israel Institute For Biological Research Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
US7429560B2 (en) 2002-09-25 2008-09-30 Georgia Tech Research Corporation Ketoamide inhibitors in chronic nerve disease
EP1558606A4 (en) 2002-10-02 2008-05-07 Bristol Myers Squibb Co DIAMINOALKYL CONTAINING LACTAM, BETA AMINO ACIDS, ALPHA AMINO ACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
US20040186044A1 (en) 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
US20040167183A1 (en) 2003-02-20 2004-08-26 The Procter & Gamble Company Phenethylamino sulfamic acids
GB0304433D0 (en) 2003-02-27 2003-04-02 Xceleron Ltd Improvements relating to chemical libraries
US7202269B2 (en) 2003-10-30 2007-04-10 Janssen Pharmaceutica N.V. GlyT2 modulators
DE602004028150D1 (de) 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
EP1729755A1 (en) * 2004-01-21 2006-12-13 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
AU2005261487A1 (en) 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
JP4194540B2 (ja) 2004-07-27 2008-12-10 キヤノン株式会社 画像形成装置
EP1871420A4 (en) 2005-04-15 2010-09-22 Univ North Carolina PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS
US20110230479A1 (en) 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
EP1893192A4 (en) 2005-06-08 2010-03-31 Univ North Carolina METHOD FOR ENABLING SURVIVAL OF NERVE CELLS BASED ON NON-PEPTIDIC AND PEPTIDIC BDNF NEUROTROPHINE MIMETICS
TWI423819B (zh) 2005-12-22 2014-01-21 Hydra Biosciences Inc 用於調節ｔｒｐａ１功能之化合物
WO2008107365A1 (en) * 2007-03-02 2008-09-12 Medivir Ab New compounds
EP2403839A4 (en) * 2009-03-06 2014-05-28 Univ North Carolina MIMETICS OF NEUROTROPHIN AND USES THEREOF
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
AU2010319349B2 (en) * 2009-11-12 2015-07-16 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US20120322799A1 (en) 2009-11-30 2012-12-20 Pharmatrophix, Inc. Deuterated compounds useful for treating neurodegenerative diseases
CN104995180A (zh) 2012-09-27 2015-10-21 特罗菲克斯制药股份有限公司 神经营养因子模拟化合物及其盐的结晶形式

Similar Documents

Publication Publication Date Title
JP2018115218A5 (ja)
JP2018024682A5 (ja)
JP2010505958A5 (ja)
JP2015511958A5 (ja)
JP2013513588A5 (ja)
JP2014507455A5 (ja)
JP2013536833A5 (ja)
PH12016501651A1 (en) Triazine compound and use thereof for medical purposes
MX354423B (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
JP2010514725A5 (ja)
JP2008536844A5 (ja)
JP2013523893A5 (ja)
JP2007530703A5 (ja)
JP2012523395A5 (ja)
JP2015500223A5 (ja)
JP2015522037A5 (ja)
AR112683A1 (es) Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende
JP2012509281A5 (ja)
JP2013510874A5 (ja)
IL266097B (en) Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
JP2013537901A5 (ja)
IL274233B1 (en) Compounds, preparations and methods for the treatment of eye disorders and skin diseases
JP2018140987A5 (ja)
JPWO2020069024A5 (ja)
RU2012136921A (ru) Твердые формы, содержащие производные циклопропиламида